Company intelligence / Profile preview

Marvel Marketing

Calgary, Alberta, Canadamarvelmarketing.ca ↗

Ownership: Private
Development stage: Other

Overview

The lead compound MB‑204 has demonstrated promising efficacy in preclinical studies across multiple neurological and neurodevelopmental disorders. Recent data show significant performance over Trofinetide in Rett syndrome models following drug cessation. cGMP synthesis and toxicology studies are complete; preparation for Phase 1 clinical trials is underway.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeSynthetic chemical derivative
Industry: Biotech

Beyond the preview

Go deeper on Marvel Marketing.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marvel Marketing.

Explore the full profile